News & Info
O'Neal Comprehensive Cancer Center at UAB: CancerLinQ Discovery
mCODE: Minimal Common Oncology Data Elements
New Mexico Cancer Center: CancerLinQ Quality Platform
CancerLinQ Practice Testimonial: New Mexico Cancer Center
CancerLinQ Practice Testimonial: Avera Cancer Institute
CancerLinQ Practice Testimonial: New England Cancer Specialists
CancerLinQ Vanguard Practices
Press Releases
Status Update on Data Required to Build a Learning Health System
Journal of Clinical Oncology
Wide adoption of electronic health records (EHRs) has raised the expectation that data obtained during routine clinical care, termed “real-world”…
First Cancer Center in U.S. History Signs on to Participate in CancerLinQ Platform
ASCO
Roswell Park Comprehensive Cancer Center of Buffalo, N.Y., has just signed an agreement to use the CancerLinQ® platform.
Growing Field of Cardio-Oncology Boosted by Collaboration Between Leading Oncology and Cardiovascular Health Organizations
ASCO
Together, ASCO’s CancerLinQ and the American Heart Association’s Precision Medicine Platform Unite to Increase Research Within Health Care Community…
ASCO Announces CancerLinQ Discovery® Research Support Grant Recipients
ASCO
The American Society of Clinical Oncology (ASCO) announced today the three recipients of its CancerLinQ Discovery® Research Support Grant.
Leading Health and Technology Organizations Release Common Cancer Data Standards to Enable Sharing Across EHR Systems and Improve Patient Care
ASCO
mCODE™, a collaboration between ASCO, MITRE, and the Alliance for Clinical Trials in Oncology Foundation identified a core set of data elements that…
CureMD™ Electronic Health Record Receives CancerLinQ Certification for Commitment to Improved Data Sharing
ASCO
ALEXANDRIA, Va.—CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), announced today that CureMD’…
Articles
Impact of COVID-19 Disease on Oncology Practice: Aromatase inhibitors and tamoxifen
CancerLinQ Data
Trends in prescription and/or administration of aromatase inhibitors and tamoxifen by month since January 2019
Impact of COVID-19 Disease on Oncology Practice: Chemotherapy Drug for Breast, Colon and Lung Cancer
George Komatsoulis, PhD, Chief of Bioinformatics
This is the second in a series of reports on the impacts of COVID-19 disease on the practice of oncology as observed through de-identified CancerLinQ…
Update on demographic data on COVID-19 patients in CancerLinQ
CancerLinQ Data
UPDATED DATA: CancerLinQ continues to monitor COVID diagnoses among active cancer patients in our database of 1.5 million total cancer patients
View Recent COVID-19 Demographics
CancerLinQ Data
CancerLinQ is monitoring COVID diagnoses among active cancer patients in our database of 1.5 million total cancer patients.
Observations on the Impact of COVID Disease on Oncology Practice from CancerLinQ: Telemedicine Encounters and Immune Checkpoint Inhibitors
George Komatsoulis, PhD, Chief of Bioinformatics
Every day, the news has new reports of changes in the delivery of health care. At CancerLinQ, a learning health system developed by the American…
Next-Generation Sequencing and the Clinical Oncology Workflow: Data Challenges, Proposed Solutions, and a Call to Action
JCO Precision Oncology
Next-generation sequencing (NGS) of tumor and germline DNA is foundational for precision oncology, with rapidly expanding diagnostic, prognostic, and…
